REPRESENT-PF Registry

Summary

This pragmatic, prospective, single-arm, multi-center, observational registry will evaluate the safety and effectiveness of PFA for the treatment of atrial fibrillation in underrepresented minority patients using FDA approved Boston Scientific PFA catheters; all data collected will be standard of care.

Eligibility

Inclusion Criteria:

* All consecutive patients classified as racial or ethnic minorities undergoing ablation using Boston Scientific FDA approved PFA catheters for AF will be included.
* De novo ablation for symptomatic paroxysmal and persistent AF (Age ≥ 18) (unless it is a repeat for a patient whose index procedure is also in the registry) who are deemed to be candidates for AF ablation by the investigator.
* Able and willing to participate in baseline and follow up evaluation over the study period
* Willing and able to provide informed consent, if applicable.

Exclusion Criteria:

* Enrolled in an investigational drug or device clinical trial or any other trial with outlined treatment plan
* Long standing persistent AF (AF \> 1 year duration)
* Repeat ablation, unless index ablation procedure was in the REPRESENT-PF registry
* Any known contra-indication to ablation procedure at the discretion of the investigator

Conditions3

Locations2 sites

Browse More Trials